ERBB2 and breast carcinoma: Approximately 15–20% of newly diagnosed breast cancers are the highly aggressive HER2+ subtype [44], and despite treatment with chemotherapy and targeted therapeutics such as trastuzumab and lapatinib, half of these patients relapse with resistant disease within one year [45].